Chemotherapy induced neutropenia market is forecasted to surge in the coming years and Aileron Therapeutics is one of the companies that are going to benefit from it majorly. The fact that it's been dropping lately only strengthens my resolve to increase my position. This will not pay off immediately, but it can bring a windfall in a few years.
There are no replies in this thread yet. Be the first to post a reply below: